IBRX Q4 2022 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$73,000-81.3% YoY

Gross Profit

-$7M-9321.9% margin

Operating Income

-$84M-115368.5% margin

Net Income

-$108M-148239.7% margin

EPS (Diluted)

$-0.27

QoQ Revenue Growth

-38.1%

Cash Flow

Operating Cash Flow

-$91M

Free Cash Flow

-$110M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$362M

Total Liabilities

$812M

Stockholders' Equity

-$447M

Cash & Equivalents

$105M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$73,000	$390,000	-81.3%
Gross Profit	-$7M	$390,000	-1844.9%
Operating Income	-$84M	-$79M	-6.2%
Net Income	-$108M	-$91M	-18.6%